Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
Abstract Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients. This study explored the effectiveness and safety of azvudine in older adults with mild or mo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08944-z |
| _version_ | 1797275665911775232 |
|---|---|
| author | Zhiguo Zhou He Zheng Gui’e Xiao Xiangping Xie Jiaxi Rang Danhong Peng |
| author_facet | Zhiguo Zhou He Zheng Gui’e Xiao Xiangping Xie Jiaxi Rang Danhong Peng |
| author_sort | Zhiguo Zhou |
| collection | DOAJ |
| description | Abstract Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients. This study explored the effectiveness and safety of azvudine in older adults with mild or moderate COVID-19. Methods This retrospective cohort study included patients aged ≥80 diagnosed with COVID-19 at the Central Hospital of Shaoyang between October and November 2022. According to the therapies they received, the eligible patients were divided into the azvudine, nirmatrelvir/ritonavir, and standard-of-care (SOC) groups. The outcomes were the proportion of patients progressing to severe COVID-19, time to nucleic acid negative conversion (NANC), and the 5-, 7-, 10-, and 14-day NANC rates from admission. Results The study included 55 patients treated with azvudine (n = 14), nirmatrelvir/ritonavir (n = 18), and SOC (n = 23). The median time from symptom onset to NANC of the azvudine, nirmatrelvir/ritonavir, and SOC groups was 14 (range, 6–25), 15 (range, 11–24), and 19 (range, 18–23) days, respectively. The median time from treatment initiation to NANC of the azvudine and nirmatrelvir/ritonavir groups was 8 (range, 4–20) and 9 (range, 5–16) days, respectively. The median length of hospital stay in the three groups was 10.5 (range, 5–23), 13.5 (range, 10–21), and 17 (range, 10–23) days, respectively. No treatment-related adverse events or serious adverse events were reported. Conclusion Azvudine showed satisfactory effectiveness and acceptable safety in older adults with mild or moderate COVID-19. Therefore, azvudine could be a treatment option for this special patient population. |
| first_indexed | 2024-03-07T15:17:44Z |
| format | Article |
| id | doaj.art-1e483a50d7aa4567801ac0a23bc88145 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-07T15:17:44Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-1e483a50d7aa4567801ac0a23bc881452024-03-05T17:48:59ZengBMCBMC Infectious Diseases1471-23342024-01-012411810.1186/s12879-023-08944-zEffectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational studyZhiguo Zhou0He Zheng1Gui’e Xiao2Xiangping Xie3Jiaxi Rang4Danhong Peng5Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, The First Hospital of ChangshaDepartment of Infectious Disease, The Central Hospital of ShaoyangDepartment of Infectious Disease, The Central Hospital of ShaoyangDepartment of Infectious Disease, The Central Hospital of ShaoyangDepartment of Nursing, The First Hospital of ChangshaDepartment of Infectious Disease, The Central Hospital of ShaoyangAbstract Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients. This study explored the effectiveness and safety of azvudine in older adults with mild or moderate COVID-19. Methods This retrospective cohort study included patients aged ≥80 diagnosed with COVID-19 at the Central Hospital of Shaoyang between October and November 2022. According to the therapies they received, the eligible patients were divided into the azvudine, nirmatrelvir/ritonavir, and standard-of-care (SOC) groups. The outcomes were the proportion of patients progressing to severe COVID-19, time to nucleic acid negative conversion (NANC), and the 5-, 7-, 10-, and 14-day NANC rates from admission. Results The study included 55 patients treated with azvudine (n = 14), nirmatrelvir/ritonavir (n = 18), and SOC (n = 23). The median time from symptom onset to NANC of the azvudine, nirmatrelvir/ritonavir, and SOC groups was 14 (range, 6–25), 15 (range, 11–24), and 19 (range, 18–23) days, respectively. The median time from treatment initiation to NANC of the azvudine and nirmatrelvir/ritonavir groups was 8 (range, 4–20) and 9 (range, 5–16) days, respectively. The median length of hospital stay in the three groups was 10.5 (range, 5–23), 13.5 (range, 10–21), and 17 (range, 10–23) days, respectively. No treatment-related adverse events or serious adverse events were reported. Conclusion Azvudine showed satisfactory effectiveness and acceptable safety in older adults with mild or moderate COVID-19. Therefore, azvudine could be a treatment option for this special patient population.https://doi.org/10.1186/s12879-023-08944-zAzvudineNirmatrelvir/ritonavirCOVID-19Older adultsTreatment effect |
| spellingShingle | Zhiguo Zhou He Zheng Gui’e Xiao Xiangping Xie Jiaxi Rang Danhong Peng Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study BMC Infectious Diseases Azvudine Nirmatrelvir/ritonavir COVID-19 Older adults Treatment effect |
| title | Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study |
| title_full | Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study |
| title_fullStr | Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study |
| title_full_unstemmed | Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study |
| title_short | Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study |
| title_sort | effectiveness and safety of azvudine in older adults with mild and moderate covid 19 a retrospective observational study |
| topic | Azvudine Nirmatrelvir/ritonavir COVID-19 Older adults Treatment effect |
| url | https://doi.org/10.1186/s12879-023-08944-z |
| work_keys_str_mv | AT zhiguozhou effectivenessandsafetyofazvudineinolderadultswithmildandmoderatecovid19aretrospectiveobservationalstudy AT hezheng effectivenessandsafetyofazvudineinolderadultswithmildandmoderatecovid19aretrospectiveobservationalstudy AT guiexiao effectivenessandsafetyofazvudineinolderadultswithmildandmoderatecovid19aretrospectiveobservationalstudy AT xiangpingxie effectivenessandsafetyofazvudineinolderadultswithmildandmoderatecovid19aretrospectiveobservationalstudy AT jiaxirang effectivenessandsafetyofazvudineinolderadultswithmildandmoderatecovid19aretrospectiveobservationalstudy AT danhongpeng effectivenessandsafetyofazvudineinolderadultswithmildandmoderatecovid19aretrospectiveobservationalstudy |